Global Optic Neuritis Treatment Market -2023-2030

Overview

Optic neuritis is a condition in which the nerve to the eye becomes inflamed or irritated. Optic neuritis is a condition that can happen because of a disease or without any specific known cause. A person who has optic neuritis might go on to develop multiple sclerosis. The most common symptoms of optic neuritis include pain with eye movement and temporary vision loss in one eye.

Moreover, optic neuritis may resolve spontaneously without any treatment. However, if the visual function is poor, a course of a steroid medication such as IV methylprednisolone with a tapering course of oral steroids is given, this afterward has been shown to speed recovery of visual function. The usual course is three days of IV steroids followed by a few days of tapering medication. When steroid therapy fails and severe vision loss persists, a treatment called plasma exchange therapy might help some people recover their vision, but studies have not yet confirmed that plasma exchange therapy is effective for optic neuritis.

Market Dynamics: Drivers

Increasing demand for novel therapeutics

There is an increasing demand for therapeutic innovative medications, which is expected to drive the global market over the forecast period. The novel therapeutics aim to address the unmet needs associated with the treatment of optic neuritis by providing alternative or complementary treatment options for better disease management.

For instance, on July 6, 2023, Horizon Therapeutics shared positive new data from a late-stage study of Uplizna (inebilizumab-cdon) in patients with neuromyelitis optica spectrum disorder (NMOSD) which is majorly characterized by the optic neuritis.

Moreover, many regulatory approvals such as FDA approvals for the development of novel therapeutics increase the trust in patients and show better results in optic neuritis treatment. For instance, on August 14, 2020, the FDA approved Genentech's Enspryng (satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody optic neuritis.

Further, the increasing prevalence of optic neuritis, increasing FDA approvals, increasing clinical trials, increasing awareness and advancements in the development of novel drugs and therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and side effects associated with the high doses of corticosteroids, the high cost of the treatment and lack of better treatment for the treatment are expected to hamper the market.

Segment Analysis

The global optic neuritis treatment market is segmented based on disease type, treatment type, distribution channel and region.

The intravenous corticosteroids segment accounted for approximately 45.3% of the optic neuritis treatment market share

The intravenous corticosteroids segment is expected to hold the largest market share over the forecast period. Intravenous corticosteroids are usually given to reduce the inflammation around the optic nerves. They can be given into a vein (infusion) for three days. These intravenous corticosteroids shorten the duration of the symptoms associated with the optic neuritis.

For instance, on April 05, 2022, Dr. Reddy's Laboratories, along with its subsidiaries, launched the Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL (methylprednisolone sodium succinate for injection, USP) in the U.S. Market approved by the U.S. Food and Drug Administration for various types of inflammatory diseases and allergic disorders.

Further, their wide availability, acceptability, and, ease of application helps to hold the largest market share. The intravenous corticosteroids can also used by combining with oral steroids, these combining medications are considered especially in cases where a single drug modality may not be sufficient. In addition, their wide adoption for the treatment of optic neuritis also increases the demand for intravenous corticosteroids.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is well-known for its strong presence of major players such as pharmaceutical companies which are involved in the research and clinical activities for the treatment of optic neuritis, which leads to the launch of novel therapeutics and alternative treatment options.

Furthermore, the United States is also known for its well-established healthcare infrastructure including hospitals, ophthalmic centers, academic and research institutes and others, which provide advanced healthcare facilities for the treatment of optic neuritis. The increasing research activities also helps to develop more advanced therapeutics for the treatment of optic neuritis in the early stages.

Competitive Landscape

The major global players in the optic neuritis treatment market include: Pfizer Inc., MERCK & CO., Inc., EyePoint Pharmaceuticals, Inc., Novartis AG, Genentech, Inc., Mallinckrodt plc, Alcon Inc., NIKSAN PHARMACEUTICAL, AbbVie Inc. and Hubei Gedian Humanwell Pharmaceutical Co., Ltd. Among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global optic neuritis treatment market. During the pandemic, non-urgent treatments are temporarily postponed. The pandemic created unprecedented challenges for pharmaceutical industries worldwide, including the global optic neuritis treatment market by temporarily disrupting many clinical trials and research activities due to the redirected focus on the COVID-19 pandemic and its related restrictions. The pandemic also disrupted the supply chain of these treatment drugs globally.

Why Purchase the Report?

• To visualize the global optic neuritis treatment market segmentation based on disease type, treatment type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of optic neuritis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global optic neuritis treatment market report would provide approximately 61 tables, 58 figures, and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies